PDCD1 and neoplasm: TAM act as effectors in anti-PD-1/PD-L1 therapy, and after treatment with anti-PD-1 or anti-PD-L1 antibodies, they show enhanced phagocytic activity and activation, thereby re-establishing their anti-tumor function [76].